Evidence map›Paper›PMID 27187778›Full record

ArticlePloS one2016

Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET.

Tetsuya Tsujikawa, Satoko Asahi, Myungmi Oh, Yoshitaka Sato, Norihiko Narita, Akira Makino, Tetsuya Mori, Yasushi Kiyono, Tatsuro Tsuchida, Hirohiko Kimura and 2 more

Open access · goldAbstract readComparative StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Advances in redox imaging for cancer diagnosis and therapy.Journal of clinical biochemistry and nutrition · 2026
    Article
  2. [Redox biology · 2022
    Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Tetsuya TsujikawaBiomedical Imaging Research Center, University of Fukui, Fukui, Japan.
Satoko AsahiDepartment of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Myungmi OhDepartment of Otolaryngology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yoshitaka SatoDepartment of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Norihiko NaritaDepartment of Otolaryngology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Akira MakinoBiomedical Imaging Research Center, University of Fukui, Fukui, Japan.
Tetsuya MoriBiomedical Imaging Research Center, University of Fukui, Fukui, Japan.
Yasushi KiyonoBiomedical Imaging Research Center, University of Fukui, Fukui, Japan.
Tatsuro TsuchidaDepartment of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Hirohiko KimuraDepartment of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Shigeharu FujiedaDepartment of Otolaryngology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Hidehiko OkazawaBiomedical Imaging Research Center, University of Fukui, Fukui, Japan.
University of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTumor redox is an important factor for cancer progression, resistance to treatments, and a poor prognosis. The aim of the present study was to define tumor redox (over-reduction) using 62Cu-diacetyl-bis(N4-methylthiosemicarbazone) (62Cu-ATSM) PET and compare its prognostic potential in head and neck cancer (HNC) with that of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG).

methodsThirty HNC patients (stage II-IV) underwent pretreatment 62Cu-ATSM and 18F-FDG PET scans. Maximum standardized uptake values (SUVATSM and SUVFDG) and tumor-to-muscle activity concentration ratios (TMRATSM and TMRFDG) were measured. Reductive-tumor-volume (RTV) was then determined at four thresholds (40%, 50%, 60%, and 70% SUVATSM), and total-lesion-reduction (TLR) was calculated as the product of the mean SUV and RTV for 62Cu-ATSM. In 18F-FDG, metabolic-tumor-volume (MTV) and total-lesion-glycolysis (TLG) were obtained at a threshold of 40%. A ROC analysis was performed to determine % thresholds for RTV and TLR showing the best predictive performance, and these were then used to determine the optimal cut-off values to stratify patients for each parameter. Progression-free-survival (PFS) and cause-specific-survival (CSS) were evaluated by the Kaplan-Meier method.

resultsThe means ± standard deviations of PFS and CSS periods were 16.4±13.4 and 19.2±12.4 months, respectively. A ROC analysis determined that the 70% SUVATSM threshold for RTV and TLR was the best for predicting disease progression and cancer death. Optimal cut-offs for each index were SUVATSM = 3.6, SUVFDG = 7.9, TMRATSM = 3.2, TMRFDG = 5.6, RTV = 2.9, MTV = 8.1, TLR = 14.0, and TLG = 36.5. When the cut-offs for TMRATSM and TLR were set as described above in 62Cu-ATSM PET, patients with higher TMRATSM (p = 0.03) and greater TLR (p = 0.02) showed significantly worse PFS, while patients with greater TLR had significantly worse CSS (p = 0.02). Only MTV in 18F-FDG PET predicted differences in PSF and CSS (p = 0.03 and p = 0.03, respectively).

conclusionTumor redox parameters measured by 62Cu-ATSM PET may be determinants of HNC patient outcomes and help define optimal patient-specific treatments.

Indexed as

Copper RadioisotopesOrganometallic CompoundsThiosemicarbazonesAgedCoordination ComplexesFemaleFluorine RadioisotopesFluorodeoxyglucose F18Head and Neck NeoplasmsHumansMaleOxidation-ReductionPositron-Emission TomographyPredictive Value of TestsPrognosisCoordination Complexescopper (II) diacetyl-di(N(4)-methylthiosemicarbazone)Copper RadioisotopesFluorine RadioisotopesFluorodeoxyglucose F18Organometallic CompoundsThiosemicarbazones

Identifiers

PMID27187778
PMCPMC4871355
OpenAlexW2400982080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.